Italia markets open in 8 hours 41 minutes

Editas Medicine, Inc. (EDIT)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a portafoglio
18,23-0,25 (-1,35%)
Alla chiusura: 04:00PM EST
21,87 +3,64 (+19,97%)
Dopo ore: 06:17PM EST

Editas Medicine, Inc.

11 Hurley Street
Cambridge, MA 02141
United States
617 401 9000
https://www.editasmedicine.com

Settore/iHealthcare
SettoreBiotechnology
Impiegati a tempo pieno235

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Mr. James C. MullenChairman, Pres & CEO100,5kN/D1959
Ms. Michelle RobertsonCFO, Principal Accounting Officer, Treasurer & Assistant Sec.647,26kN/D1967
Dr. Lisa A. Michaels M.D.Exec. VP & Chief Medical Officer213,47kN/D1965
Dr. Feng ZhangCo-Founder & Scientific Advisory Board MemberN/DN/DN/D
Dr. George McDonald Church Ph.D.Co-Founder & Scientific Advisory Board MemberN/DN/D1954
Dr. J. Keith Joung M.D., Ph.D.Co-Founder & Scientific Advisory Board MemberN/DN/DN/D
Dr. David R. Liu Ph.D.Co-Founder & Scientific Advisory Board MemberN/DN/DN/D
Mr. Harry R. Gill IIISr. VP of OperationsN/DN/D1961
Dr. Mark S. ShearmanExec. VP & Chief Scientific OfficerN/DN/D1960
Ron MoldaverInvestor RelationsN/DN/DN/D
Gli importi risalgono al giorno 31 dicembre 2020 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary genome editing platform based on CRISPR technology to target genetically addressable diseases and therapeutic areas. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa 4, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumors; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has a early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio and collaboration with m BlueRock Therapeutics LP. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

Governance aziendale

L'ISS Governance QualityScore di Editas Medicine, Inc. al 26 settembre 2021 è 8. I criteri di valutazione fondamentali sono revisione: 1; Consiglio di Amministrazione: 8; diritti degli azionisti: 8; retribuzione: 8.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.